✦ LIBER ✦

Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial

✍ Scribed by Kelly-Anne Phillips; Karin Ribi; Zhuoxin Sun; Alisa Stephens; Alastair Thompson; Vernon Harvey; Beat Thürlimann; Fatima Cardoso; Olivia Pagani; Alan S. Coates; Aron Goldhirsch; Karen N. Price; Richard D. Gelber; Jürg Bernhard

Book ID: 113507226
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 491 KB
Volume: 19
Category: Article
ISSN: 0960-9776
DOI: 10.1016/j.breast.2010.03.025

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cognitive function in postmenopausal bre

Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial

✍ Kelly-Anne Phillips; Julie Aldridge; Karin Ribi; Zhuoxin Sun; Alastair Thompson; 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 241 KB

341 POSTER Letrozole is cost-effective v

341 POSTER Letrozole is cost-effective versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer: BIG-1-98

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 148 KB

S4 Letrozole vs. Tamoxifen as adjuvant e

S4 Letrozole vs. Tamoxifen as adjuvant endocrine therapy for postmenopausal women in receptor-positive breast cancer. BIG 1-98: A prospective randomized double-blind phase III study

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 73 KB

Interpreting breast international group

Interpreting breast international group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer

✍ Meredith M Regan; Karen N Price; Anita Giobbie-Hurder; Beat Thürlimann; Richard 📂 Article 📅 2011 🏛 BioMed Central 🌐 English ⚖ 368 KB

0161 Letrozole vs. tamoxifen as adjuvant

0161 Letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Update of the BIG 1-98 primary core analysis

✍ B. Thürlimann 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Adjuvant letrozole versus tamoxifen acco

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial

✍ Birgitte B Rasmussen; Meredith M Regan; Anne E Lykkesfeldt; Patrizia Dell'Orto; 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 213 KB